ASCO 2025 Signals a New Chapter in Myelofibrosis Care The 2025 ASCO Annual Meeting delivered early insights into the future of myelofibrosis (MF) treatments. For Clinical Services International (CSI), a trusted sourcing partner for global oncology trials, this represents a significant scientific milestone. What’s New in MF and Why It Matters JAK inhibitors continue to be foundational in MF treatment, with ruxolitinib remaining a strong first-line option. However, ASCO 2025 hi